United Therapeutics Corporation - Common Stock (NQ:UTHR)

549.16 +16.38 (+3.07%)

Delayed Quote Updated: 4:00 PM EDT, Oct 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about United Therapeutics Corporation - Common Stock

< Previous 1 2

...

11 12 13 14 15 16 17 18 Next >

United Therapeutics Stops Late-Stage Tyvaso Study In Lung Disease ↗

September 20, 2022

Via Benzinga

United Therapeutics Releases Its Annual Corporate Responsibility Report and Inaugural Public Benefit Report

September 12, 2022

From United Therapeutics Corporation

Via Business Wire

United Therapeutics Prevails in Dry Powder Inhaler Patent Litigation

August 31, 2022

From United Therapeutics Corporation

Via Business Wire

United Therapeutics to Feature Clinical Data at the European Society of Cardiology Congress 2022 and the European Respiratory Society International Congress 2022

August 24, 2022

From United Therapeutics Corporation

Via Business Wire

United Therapeutics: Return On Capital Employed Overview ↗

August 08, 2022

Via Benzinga

Expert Ratings for United Therapeutics ↗

May 24, 2022

Within the last quarter, United Therapeutics (NASDAQ:UTHR) has observed the following analyst ratings:

Via Benzinga

New Drugs in Pipeline for Hypertension, the Silent Global Pandemic

August 10, 2022

Via Investor Brand Network

Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial ↗

August 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

New Drugs in Pipeline for Hypertension, the Silent Global Pandemic

August 10, 2022

NetworkNewsWire Editorial Coverage New York, NY – August 10, 2022 – In medicine, there is a term called “clinical inertia,” or the case of what someone doesn’t know — or what they ignore — could kill...

Via FinancialNewsMedia

United Therapeutics Corporation Reports Second Quarter 2022 Financial Results

August 03, 2022

From United Therapeutics Corporation

Via Business Wire

Earnings Outlook For United Therapeutics ↗

August 02, 2022

United Therapeutics (NASDAQ:UTHR) is set to give its latest quarterly earnings report on Wednesday, 2022-08-03. Here's what investors need to know before the announcement. Analysts estimate that United...

Via Benzinga

Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review ↗

August 05, 2022

The Nasdaq and small caps rose while the S&P 500 is hitting resistance.

Via Investor's Business Daily

United Therapeutics Corporation to Report Second Quarter 2022 Financial Results Before the Market Opens on Wednesday, August 3, 2022

July 27, 2022

From United Therapeutics Corporation

Via Business Wire

7 Best Pharmaceutical Stocks to Buy Now ↗

July 20, 2022

These investments represent the best pharmaceutical stocks. Each offers incredible upside potential in the post-pandemic world.

Via InvestorPlace

Swing Trading Stock Watchlist For The Week Of July 11 And Beyond ↗

July 09, 2022

The stock market's health is improving, but a likely bottom has not been confirmed yet. That means I’m buying some stocks (swing trades), but I'm not loading up yet. Let's see what I'm looking at.

Via Talk Markets

7 Biotech Stocks With Key Catalysts Coming in July ↗

June 27, 2022

Biotech stocks have had a rocky few months, but many are on the mend. These picks should provide investors both flexibility and growth.

Via InvestorPlace

Buy These 3 Low-Beta Stocks To Sail Through A Choppy Market ↗

June 25, 2022

Creating a portfolio of low-beta stocks is of utmost importance since the securities will deliver healthy returns and provide a shield against volatile market conditions.

Via Talk Markets

Corcept Stock Near Buy Point; Strength Rating Jumps To 91 ↗

June 23, 2022

The new 91 RS Rating means that Corcept stock has outperformed 90% of all other stocks over the past year.

Via Investor's Business Daily

Will Investors Notice Exciting Sign On United Therapeutics's Chart? ↗

June 10, 2022

If history is any guide, there may be good fortune ahead for shares of United Therapeutics (NASDAQ:UTHR). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish...

Via Benzinga

United Therapeutics Provides an Update on Its Organ Printing Programs

June 06, 2022

From United Therapeutics Corporation

Via Business Wire

United Therapeutics Corporation to Present at the Jefferies Healthcare Conference

June 03, 2022

From United Therapeutics Corporation

Via Business Wire

Short Volatility Alert: United Therapeutics Corporation ↗

May 26, 2022

On Wednesday, shares of United Therapeutics Corporation (NASDAQ: UTHR) experienced volatile short activity. After the activity, the stock price went up 4.31% to $228.39. The...

Via Benzinga

United Therapeutics Stock Sees RS Rating Jump To 89; Earns 'Blue Dot' ↗

May 24, 2022

United Therapeutics stock had its Relative Strength (RS) Rating upgraded to 89 Tuesday, from 71 a day earlier.

Via Investor's Business Daily

The Daily Biotech Pulse: INmune Bio's Planned Alzheimer's Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures ↗

May 24, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

United Therapeutics Announces FDA Approval of Tyvaso DPI™

May 24, 2022

From United Therapeutics Corporation

Via Business Wire

United Therapeutics's Return on Invested Capital Insights ↗

May 18, 2022

According to Benzinga Pro, during Q1, United Therapeutics (NASDAQ:UTHR) earned $239.90 million, a 113.81% increase from the preceding quarter. United Therapeutics also posted a total of $461.90 million...

Via Benzinga

7 Biotech Stocks With Key Catalysts for May ↗

May 11, 2022

The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns.

Via InvestorPlace

The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints ↗

May 04, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Recap: United Therapeutics Q1 Earnings ↗

May 04, 2022

United Therapeutics (NASDAQ:UTHR) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

United Therapeutics Corporation Reports First Quarter 2022 Financial Results

May 04, 2022

From United Therapeutics Corporation

Via Business Wire

< Previous 1 2

...

11 12 13 14 15 16 17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.